Metabolic biomarkers of risperidone-induced weight gain in drug-naive patients with schizophrenia

BackgroundRisperidone is a commonly prescribed antipsychotic drug with a potential side effect of weight gain. However, the pathophysiological mechanism is still poorly understood. Here, we sought to identify potential biomarkers of risperidone-induced weight gain by using a targeted metabolomics approach. MethodsWe enrolled 30 subjects who received risperidone monotherapy for 8 weeks from a prospective longitudinal cohort study for drug-naive schizophrenia patients. Plasma metabolites were measured by targeted metabolomics Biocrates MxP (R) Quant 500 Kit at baseline and 8-week follow-up. ResultsAfter 8 weeks of risperidone treatment, the levels of 48 differential metabolites were upregulated, including lysophosphatidylcholines (2), phosphatidylcholines (PC) (8), cholesteryl esters (CE) (3), and triglycerides (35), while 6 differential metabolites namely PC aa C38:6, methionine (Met), alpha-aminobutyric acid (AABA), TrpBetaine, CE (22:6), and Taurocholic acid (TCA) were downregulated. Interestingly, the reduction of PC aa C38:6, AABA and CE (22:6) was linearly related with increased BMI. Further multiple regression analysis showed that the changes of PC aa C38:6 and AABA were independent contributors of increased BMI. In addition, baseline levels of PC aa C36:5, CE (20:5) and AABA had positive relationships with the change of BMI. ConclusionOur findings indicate phosphatidylcholines and amino acids may serve as biomarkers for risperidone-induced weight gain.

Automated summary

In this study, potential biomarkers of risperidone-induced weight gain were identified using a targeted metabolomics approach. The results suggest that phosphatidylcholines and amino acids may serve as biomarkers for risperidone-induced weight gain.